India Anti Hypertensive Drugs Market

ID: MRFR/HC/54829-HCR 200 Pages Satyendra Maurya Last Updated: September 17, 2026
India Antihypertensive Drugs Market India Antihypertensive Drugs Market Research Report: By Drug Class (Diuretics, ACE Inhibitors, Beta Blockers, Calcium Channel Blockers, Angiotensin II Receptor Antagonists), By Administration Route (Oral, Injectable, Transdermal), By Indication (Essential Hypertension, Secondary Hypertension, Hypertensive Crisis) andBy Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)- Forecast to 2035
India Anti Hypertensive Drugs Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.99%
2018 Market Size$ 4.36 Billion
2024 Market Size$ 1.25 Billion
2035 Market Size$ 1.93 Billion
Key Players
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Dr. Reddy's Laboratories Ltd
Lupin Ltd
Aurobindo Pharma Ltd
Torrent Pharmaceuticals Ltd
Trends
  • Rising Prevalence of Hypertension
  • Innovative Drug Development
  • Digital Health Integration
Opportunities
  • Rising Geriatric Population
  • Government Health Initiatives
  • Rising Awareness and Education
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 India Anti Hypertensive Drugs Market, BY Drug Class (USD Billion)
      1. 4.1.1 Angiotensin Converting Enzyme Inhibitors
      2. 4.1.2 Angiotensin II Receptor Blockers
      3. 4.1.3 Calcium Channel Blockers
      4. 4.1.4 Diuretics
      5. 4.1.5 Beta Blockers
    2. 4.2 India Anti Hypertensive Drugs Market, BY Administration Route (USD Billion)
      1. 4.2.1 Oral
      2. 4.2.2 Intravenous
      3. 4.2.3 Subcutaneous
      4. 4.2.4 Transdermal
    3. 4.3 India Anti Hypertensive Drugs Market, BY Therapeutic Use (USD Billion)
      1. 4.3.1 Hypertension
      2. 4.3.2 Heart Failure
      3. 4.3.3 Chronic Kidney Disease
      4. 4.3.4 Post-Myocardial Infarction
    4. 4.4 India Anti Hypertensive Drugs Market, BY Patient Demographics (USD Billion)
      1. 4.4.1 Elderly
      2. 4.4.2 Adults
      3. 4.4.3 Pediatric
      4. 4.4.4 Pregnant Women
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the India Anti Hypertensive Drugs Market
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the India Anti Hypertensive Drugs Market
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Sun Pharmaceutical Industries Ltd (IN)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Cipla Ltd (IN)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Dr. Reddy's Laboratories Ltd (IN)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Lupin Ltd (IN)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Aurobindo Pharma Ltd (IN)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Torrent Pharmaceuticals Ltd (IN)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Zydus Cadila (IN)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Alkem Laboratories Ltd (IN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Mylan Laboratories Ltd (IN)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 INDIA MARKET ANALYSIS BY DRUG CLASS
    3. 6.3 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    4. 6.4 INDIA MARKET ANALYSIS BY THERAPEUTIC USE
    5. 6.5 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    6. 6.6 KEY BUYING CRITERIA OF INDIA ANTI HYPERTENSIVE DRUGS MARKET
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF INDIA ANTI HYPERTENSIVE DRUGS MARKET
    9. 6.9 DRIVERS IMPACT ANALYSIS: INDIA ANTI HYPERTENSIVE DRUGS MARKET
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDIA ANTI HYPERTENSIVE DRUGS MARKET
    11. 6.11 SUPPLY / VALUE CHAIN: INDIA ANTI HYPERTENSIVE DRUGS MARKET
    12. 6.12 INDIA ANTI HYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, 2024 (% SHARE)
    13. 6.13 INDIA ANTI HYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
    14. 6.14 INDIA ANTI HYPERTENSIVE DRUGS MARKET, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
    15. 6.15 INDIA ANTI HYPERTENSIVE DRUGS MARKET, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
    16. 6.16 INDIA ANTI HYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC USE, 2024 (% SHARE)
    17. 6.17 INDIA ANTI HYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC USE, 2024 TO 2035 (USD Billion)
    18. 6.18 INDIA ANTI HYPERTENSIVE DRUGS MARKET, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    19. 6.19 INDIA ANTI HYPERTENSIVE DRUGS MARKET, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG CLASS, 2026-2035 (USD Billion)
      2. 7.2.2 BY ADMINISTRATION ROUTE, 2026-2035 (USD Billion)
      3. 7.2.3 BY THERAPEUTIC USE, 2026-2035 (USD Billion)
      4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

India Anti Hypertensive Drugs Market Segmentation

India Anti Hypertensive Drugs Market By Drug Class (USD Billion, 2022-2035)

  • Angiotensin Converting Enzyme Inhibitors
  • Angiotensin II Receptor Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Beta Blockers

India Anti Hypertensive Drugs Market By Administration Route (USD Billion, 2022-2035)

  • Oral
  • Intravenous
  • Subcutaneous
  • Transdermal

India Anti Hypertensive Drugs Market By Therapeutic Use (USD Billion, 2022-2035)

  • Hypertension
  • Heart Failure
  • Chronic Kidney Disease
  • Post-Myocardial Infarction

India Anti Hypertensive Drugs Market By Patient Demographics (USD Billion, 2022-2035)

  • Elderly
  • Adults
  • Pediatric
  • Pregnant Women

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.